A Randomized, Double-Blind, Placebo and Comparator-Controlled Crossover Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes
Latest Information Update: 30 Dec 2024
At a glance
- Drugs CT 868 (Primary) ; Liraglutide
- Indications Type 1 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Carmot Therapeutics; Roche
Most Recent Events
- 27 Dec 2024 Status changed from recruiting to completed.
- 29 Jan 2024 According to a Carmot Therapeutics media release, Carmot Therapeutics acquired by the Roche Group (Roche).
- 21 Jun 2023 Planned End Date changed from 1 Dec 2023 to 1 Feb 2024.